Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA-Reference-Cited by-同舟云学术

Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA

Published:2018-10-05 Issue:11 Volume:34 Page:507-512
ISSN:1172-0360
Container-title:Drugs & Therapy Perspectives
language:en
Short-container-title:Drugs Ther Perspect

Author:

Heo Young-A

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40267-018-0561-8/fulltext.html

Reference21 articles.

1. Milling TJ Jr, Frontera J. Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding. Am J Manag Care. 2017;23(4 Suppl):S67–80.

2. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113(5):931–42.

3. Milling TJ, Clark CL, Feronti C, et al. Management of factor Xa inhibitor-associated life-threatening major hemorrhage: a retrospective multi-center analysis. Am J Emerg Med. 2018;36:396–402.

4. Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273–81.

5. Dabi A, Koutrouvelis AP. Reversal strategies for intracranial hemorrhage related to direct oral anticoagulant medications. Crit Care Res Pract. 2018;2018(4907164):1–11.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study;World Neurosurgery: X;2024-07

2. Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds;Clinical and Applied Thrombosis/Hemostasis;2022-01

3. Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis;Cureus;2021-12-23

4. Proximale osteosynthetisch versorgte Femurfrakturen: Der Versorgungszeitpunkt verzögert sich bei vorbestehender Antikoagulation;Der Unfallchirurg;2020-11-27

5. Institutional Experience of Using Andexanet Alfa;Cureus;2020-07-13